Detailed Narrative
Robust Q3 FY26 Financial Performance
Rubicon Research Limited delivered a strong Q3 FY26, with revenue from operations reaching INR476 crores, a 52% increase year-on-year. This growth translated into significant profitability improvements, as EBITDA grew 59% year-on-year to INR112 crores, and Profit After Tax (PAT) surged 91% year-on-year to INR73 crores. The company reported an Earnings Per Share (EPS) of 4.41 rupees for the quarter, reflecting broad-based growth across both new launches and existing products, with 98% of revenues derived from US dollars.
Strategic R&D Investments and Increasing Productivity
The company maintained its commitment to R&D, with expenses for Q3 FY26 at INR52 crores, representing 11% of revenue, aligning with its guidance of 10-11% for the next several years. Management highlighted a significant improvement in R&D productivity, with the R&D to incremental revenue multiplier increasing from 3.3x (FY21-FY24) to 5.7x (FY23-FY26). This improvement is attributed to a strategic shift towards specialty, drug-device combinations, and branded products, with confidence in maintaining productivity upward of 5x and an aggregate R&D spend above INR500 crores for FY26-FY28.
Pithampur Facility Expansion and Future Capacity
The acquisition of the Pithampur facility, with handover in June 2025, is a key strategic move to build capacity and capability, including high-potent oncology, hormones, and steroids. The facility is on track for operationalization by mid-2026 calendar year, with commercialization expected in Q1 CY27. This expansion is crucial to meet higher-than-anticipated demand and is expected to provide significant leverage for scaling up business, although increased outsourcing in the near term to meet demand is currently pressuring gross margins.
Stable Operating Margins Amidst Growth
Despite the near-term pressure on gross margins due to increased outsourcing, management reaffirmed its confidence in maintaining the operating EBITDA margin within the 22%-23% range. The specialty share of gross profit has increased to 31-32% in Q2 and Q3 FY26, up from 26.9% in FY25, indicating a favorable product mix. Once the Pithampur facility ramps up and reliance on outsourced manufacturing reduces, the company is confident of returning to its earlier gross margin range of 67%-68%.
Healthy Cash Flow and Capital Efficiency
Rubicon demonstrated healthy cash flow generation, with net cash flow from operating activities for Q3 FY26 at INR35 crores (after tax) and INR81 crores before tax. Year-to-date net cash flow from operations stood at INR140 crores. The company's Return on Capital Employed (ROCE) improved to 34%, reflecting a strong focus on capital efficiency. Net working capital at INR607 crores (132 days) was largely in line with previous periods, with 25-30% of inventory allocated to recent and upcoming launches.
Global Expansion and Strategic Pipeline
The company is actively pursuing global expansion beyond the US, with business development teams working on building presence in markets like Saudi Arabia and Europe. While specific market offers are not yet detailed, the strategy involves leveraging its product basket of innovative products across these geographies. The pipeline includes promising areas like intranasal drug delivery for conditions such as Parkinson's disease and traumatic brain injury, with early studies showing significantly enhanced delivery efficiency.
Board of Directors Update
Rubicon Research Limited announced the appointment of Dr. Pradnya Saravade as an Independent Director to its Board. Concurrently, Mr. Anand Agarwal, a nominee from General Atlantic, stepped down. These changes ensure that the board is now equally comprised of Promoter Directors, General Atlantic nominees, and four Independent Directors, enhancing governance and strategic oversight.